N-Acetyl Epitalon Amidate
Evidence: EExperimental / Early Research
Evidence Snapshot
What this grade covers
E for therapeutic efficacy; A-/B for identity only if exact analytical identity is independently confirmed. This subject is primarily useful as an identity / evidence-transfer boundary case study, not a therapeutic-evidence page.
Regulatory Context
No approved therapeutic indication should be claimed for the exact modified analogue.
Research Takeaway
N-Acetyl Epitalon Amidate is a chemically modified analogue of parent AEDG/Epitalon, not automatically the same experimental entity.
See all 5 evidence claims →Quick Summary
N-Acetyl Epitalon Amidate (Ac-AEDG-NH2) is a commercially described N-terminally acetylated, C-terminally amidated analogue of AEDG (Epitalon/Epithalon). No direct indexed therapeutic study of the exact modified molecule has been identified; evidence for the parent peptide Epitalon/AEDG does not transfer to this distinct chemical entity.
Mechanism & Research Overview
No direct mechanistic study of the exact N-acetylated, C-terminally amidated analogue was identified. Improved stability/bioavailability claims commonly made for terminal peptide modifications require direct analytical/pharmacokinetic evidence and must not be inferred from the parent compound.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
N-Acetyl Epitalon Amidate is a chemically modified analogue of parent AEDG/Epitalon, not automatically the same experimental entity.
Sources: MitoCore editorial search audit: no direct indexed study located for Ac-AEDG-NH2 (N-Acetyl Epitalon Amidate)
Supported
Parent Epitalon studies do not establish efficacy, pharmacokinetics, stability, safety, or dosing for Ac-AEDG-NH2. The same rule applies to N-acetylated, amidated, PEGylated, fragmented, or salt/formulation variants generally.
Sources: MitoCore editorial search audit: no direct indexed study located for Ac-AEDG-NH2 (N-Acetyl Epitalon Amidate)
Supported
No direct PubMed-indexed, PMC-indexed, or clinical-trial evidence for the exact modified analogue was identified. A negative search does not prove no unpublished/non-indexed experiment exists; the correct wording is that no direct indexed study was identified in this research pass.
Sources: MitoCore editorial search audit: no direct indexed study located for Ac-AEDG-NH2 (N-Acetyl Epitalon Amidate)
Supported
Improved stability/bioavailability claims commonly made for terminal peptide modifications require direct analytical/pharmacokinetic evidence and must not be inferred from the parent compound.
Supported
No approved therapeutic indication should be claimed for the exact modified analogue.
Sources: MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Safety Consideration
Commercial pages frequently extrapolate parent AEDG/Epitalon findings to this distinct modified molecule. That transfer is not scientifically valid without direct study of the modified molecule.Safety Consideration
No direct PubMed-indexed, PMC-indexed, or clinical-trial evidence for the exact modified analogue was identified in two independent research passes.
Research Areas Being Studied
Research areas discussed on this page reflect the Experimental / Early Research category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
Human Studies & Clinical Data
No Human Studies & Clinical Data Listed Yet
This section will be updated as sources are added.
Animal / Cell / Preclinical Data
No Animal / Cell / Preclinical Data Listed Yet
This section will be updated as sources are added.
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check | 2026 | Direct search performed 2026-08-17 for FDA drug-approval status and ClinicalTrials.gov interventional-trial registration for PNC-27, Pancragen, Bronchogen, Testagen, Chonluten, Prostamax, Ovagen, and N-Acetyl Epitalon Amidate (Ac-AEDG-NH2), including known aliases and sequence names. No FDA-approved drug product was identified for any of the eight compounds. No registered ClinicalTrials.gov interventional trial was identified for any of the eight compounds. All eight are marketed exclusively through peptide/research-chemical vendors as research-use-only products, not as approved medicines. Absence from these searches is not itself a formal FDA determination and does not establish safety or ineffectiveness -- it establishes only that no approval or registered trial was located in this search pass. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes an evidence-transfer boundary case and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-08-17.
Follow research updates for N-Acetyl Epitalon Amidate
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.